Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations
Open accessAbstract
BACKGROUND: The aim of this study was to correlate histological features and molecular characteristics in anaplastic oligodendrogliomas (AOs). METHODS: The histological characteristics of 203 AO patients, enrolled in the French national network POLA, were analyzed. The genomic profiles of 191 cases were studied using genomic arrays. IDH mutational status was assessed by immunohistochemistry and direct sequencing. RESULTS: 1p/19q codeletion was present in 79% of cases and was associated with alpha-internexin expression (P < 10(-4)), IDH1/2 mutation (P < 10(-4)), chromosome 4 loss (P < 10(-3)), and better overall survival (P < 10(-4)). Based on mitotic index, microvascular proliferation (MVP), and necrosis, 3 groups of 1p/19q codeleted AOs were identified: (group 1) AO with more than 5 mitoses per 10-HPF, no MVP, and no necrosis; (group 2) AO with MVP and no necrosis; and (group 3) AO with MVP and necrosis. Compared with group 1, groups 2 and 3 AOs had a higher mean Ki-67 proliferation index and a higher rate of 9p and 9q losses. Compared with group 2, group 3 AOs had a higher number of chromosomal alterations including chromosome 4 loss. In the subgroup of 157 1p/19q codeleted AOs, chromosomal instability was associated with shorter progression-free survival (P = .024) and shorter overall survival (P = .023). CONCLUSIONS: The present study shows that oligodendrogliomas with classic histological features remain a molecularly heterogeneous entity and should be stratified according to 1p/19q status because of its major prognostic relevance. Moreover, 1p/19q codeleted AOs are also heterogeneous. Interestingly, mitotic index, MVP, and necrosis help to classify them into 3 groups associated with distinct genomic alterations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These grading criteria are subject to inter-rater variability, and the reliability of these benchmarks as a predictor of patient outcome has been called into question.
“These criteria are subject to inter-rater variability, and accordingly, the reliability of these benchmarks as a predictor of patient outcome have been called into question [7,12,13,14].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [12]
The paper says histological classification can depend on how a pathologist classifies the tumor, with necrosis then changing its grade (section labeled Abstract; page unavailable). It also says necrosis’s prognostic significance is controversial and cautions in the Discussion that short follow-up prevents definitive prognostic conclusions. It does not directly assess inter-rater variability or establish that such variability is why the grading criteria’s outcome prediction is questioned. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,422 · see citing works
Self-citationVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · see citing works
<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works
van den Bent, M. J., Brandes, A. A., TAPHOORN, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Grisold, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,220 · see citing works
Self-citationCairncross, G. J., Wang, M., Shaw, E., Jenkins, R. B., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperrière, N., Curran, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,152 · see citing works
Jenkins, R. B., Blair, H. E., Ballman, K. V., Giannini, C., Arusell, R. M., Law, M., Flynn, H. C., Passe, S. M., Felten, S. J., Brown, P. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1796 · Cited by 762 · see citing works
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaïh, A., Laigle–Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 532 · see citing works
Self-citationGriffin, C. A., Burger, P. C., Morsberger, L. A., Yonescu, R., Swierczynski, S. L., WEINGART, J. D., & Murphy, K. M. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000235122.98052.8f · Cited by 302 · see citing works
Temozolomide for low-grade gliomas
Kaloshi, G., Benouaich‐Amiel, A., Diakité, F., Taillibert, S., Lejeune, J., Laigle–Donadey, F., Renard, M.-A., Iraqi, W., Idbaïh, A., Paris, S., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000262034.26310.a2 · Cited by 285 · see citing works
Self-citationAll the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaïh, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 274 · see citing works
Self-citationOligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
Giannini, C., Scheithauer, B. W., Weaver, A. L., Burger, P. C., Kros, J. M., Mork, S., Graeber, M. B., Bauserman, S., Buckner, J. C., Burton, J., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.3.248 · Cited by 219 · see citing works
Mueller, W. C., Hartmann, C. J., Hoffmann, A., Lanksch, W., Kiwit, J. C. W., Tonn, J. C., Veelken, J., Schramm, J., Weller, M., Wiestler, O. D., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64183-1 · Cited by 178 · see citing works
Miller, C. R., Dunham, C. P., Scheithauer, B. W., & Perry, A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1497 · Cited by 178 · see citing works
Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features
Jenkinson, M. D. (2006) · Brain · doi:10.1093/brain/awl108 · Cited by 162 · see citing works
Perry, A., Aldape, K., George, D. H., & Burger, P. C. (2004) · Cancer · doi:10.1002/cncr.20625 · Cited by 148 · see citing works
Giannini, C., Burger, P. C., Berkey, B. A., Cairncross, J. G., Jenkins, R. B., Mehta, M. P., Curran, W. J., & Aldape, K. D. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00129.x · Cited by 134 · see citing works
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors
McDonald, J. M., See, S. J., Tremont, I., Colman, H., Gilbert, M. R., Groves, M. D., Burger, P. C., Louis, D. N., Giannini, C., Fuller, G. N., et al. (2005) · Cancer · doi:10.1002/cncr.21338 · Cited by 104 · see citing works
Reyes-Botero, G., Dehais, C., Idbaïh, A., Martin-Duverneuil, N., Lahutte, M., Carpentier, C., Letouzé, É., Chinot, O. L., Loiseau, H., Honnorat, J., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not235 · Cited by 69 · see citing works
Self-citationMorphologic and molecular genetic aspects of oligodendroglial neoplasms
Bigner, S. H., Rasheed, B., Wiltshire, R. N., & McLendon, R. E. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.52 · Cited by 58 · see citing works
Kim, J. W., Park, C., Park, S., Kim, Y. H., Han, J., Kim, C., Sohn, C., Chang, K., & Jung, H. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.178806 · Cited by 55 · see citing works
Mokhtari, K., Ducray, F., Kros, J. M., Gorlia, T., Idbaïh, A., TAPHOORN, M. J. B., Wesseling, P., Hoang‐Xuan, K., van den Bent, M. J., & Sanson, M. (2011) · Cancer · doi:10.1002/cncr.25827 · Cited by 37 · see citing works
Self-citationCraig, J. M., Vena, N., Ramkissoon, S. H., Idbaïh, A., Fouse, S. D., Özek, M. M., Sav, A., Hill, D. A., Margraf, L. R., Eberhart, C. G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038881 · Cited by 37 · see citing works
Godfraind, C., Rousseau, E., Ruchoux, M. M., Scaravilli, F., & Vikkula, M. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00484.x · Cited by 34 · see citing works
Idbaïh, A., Ducray, F., Dehais, C., Courdy, C., Carpentier, C., de Bernard, S., Uro‐Coste, E., Mokhtari, K., Jouvet, A., Honnorat, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045950 · Cited by 31 · see citing works
Self-citationCoulibaly, B., Nanni, I., Quilichini, B., Gaudart, J., Métellus, P., Fina, F., Boucard, C., Chinot, O. L., Ouafik, L., & Figarella‐Branger, D. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.09.020 · Cited by 23 · see citing works
Self-citation
Flagged first, then by citations
1 of the 27 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Prognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 347 · see citing works
Oligodendroglioma: pathology, molecular mechanisms and markers
Wesseling, P., van den Bent, M. J., & Perry, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1424-1 · Cited by 228 · see citing works
Diffuse Infiltrating Oligodendroglioma and Astrocytoma
van den Bent, M. J., Smits, M., Kros, J. M., & Chang, S. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6737 · Cited by 175 · see citing works
Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov182 · Cited by 163 · see citing works
Classification of adult‐type diffuse gliomas: Impact of the World Health Organization 2021 update
Whitfield, B. T., & Huse, J. T. (2022) · Brain Pathology · doi:10.1111/bpa.13062 · Cited by 162 · see citing works
Schiff, D., van den Bent, M. J., Vogelbaum, M. A., Wick, W., Miller, C. R., TAPHOORN, M. J. B., Pope, W. B., Brown, P. D., Platten, M., Jalali, R., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz033 · Cited by 125 · see citing works
Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma
Hu, X., Martínez-Ledesma, E., Zheng, S., Kim, H., Barthel, F. P., Jiang, T., Hess, K. R., & Verhaak, R. G. W. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now285 · Cited by 114 · see citing works
Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort
For POLA Network, Tabouret, É., Nguyễn, A. T., Dehais, C., Carpentier, C., Ducray, F., Idbaïh, A., Mokhtari, K., Jouvet, A., Uro‐Coste, E., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1611-8 · Cited by 107 · see citing works
Self-citationKamoun, A., Idbaïh, A., Dehais, C., Elarouci, N., Carpentier, C., Letouzé, É., Colin, C., Mokhtari, K., Jouvet, A., Uro‐Coste, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms11263 · Cited by 104 · see citing works
Self-citationFigarella-Branger, D. F., Lechapt, E., Tabouret, É., Jünger, S. T., de Paula, A. M., Bouvier, C., Colin, C., Jouvet, A., Forest, F., Andreiuolo, F. D. M., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now025 · Cited by 95 · see citing works
Self-citationvan den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae107 · Cited by 88 · see citing works
Self-citationLa classification de l’OMS 2021 des tumeurs du système nerveux central
Figarella-Branger, D. F., Appay, R., Métais, A., Tauziède‐Espariat, A., Colin, C., Rousseau, A., & Varlet, P. (2021) · Annales de Pathologie · doi:10.1016/j.annpat.2021.11.005 · Cited by 74 · see citing works
Self-citationBeyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas
Mirchia, K., & Richardson, T. E. (2020) · Cancers · doi:10.3390/cancers12071817 · Cited by 64 · see citing works
Updates on the WHO diagnosis of IDH-mutant glioma
Reuß, D. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04250-5 · Cited by 59 · see citing works
Tabouret, É., Tchoghandjian, A., Denicolaï, E., Delfino, C., Métellus, P., Graillon, T., Boucard, C., Nanni, I., Padovani, L., Ouafik, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3256 · Cited by 58 · see citing works
Self-citationGrade II and III Oligodendroglioma and Astrocytoma
van den Bent, M. J., & Chang, S. M. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.005 · Cited by 41 · see citing works
Pouget, C., Hergalant, S., Lardenois, É., Lacomme, S., Houlgatte, R., Carpentier, C., Dehais, C., Rech, F., Taillandier, L., Sanson, M., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12788 · Cited by 35 · see citing works
Self-citationKacimi, S. E. O., Dehais, C., Feuvret, L., Chinot, O. L., Carpentier, C., Bronnimann, C., Vauléon, É., Djelad, A., Moyal, E. C., Langlois, O., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00049 · Cited by 33 · see citing works
Self-citationFigarella-Branger, D. F., Mokhtari, K., Dehais, C., Carpentier, C., Colin, C., Jouvet, A., Uro‐Coste, E., Forest, F., Maurage, C., Vignaud, J.-M., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now085 · Cited by 32 · see citing works
Self-citationLow-grade and anaplastic oligodendroglioma
van den Bent, M. J., Bromberg, J. E. C., & Buckner, J. C. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00022-0 · Cited by 31 · see citing works
Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors
Kim, H. S., & Lee, D. Y. (2022) · Biomedicines · doi:10.3390/biomedicines10010096 · Cited by 29 · see citing works
Anaplastic glioma: current treatment and management
Rhun, É. L., Taillibert, S., & Chamberlain, M. C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1042455 · Cited by 25 · see citing works
POLA network, Grandin, N., Pereira, B., Cohen, C., Billard, P., Dehais, C., Carpentier, C., Idbaïh, A., Bielle, F., Ducray, F., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0833-0 · Cited by 20 · see citing works
Self-citationPark, Y. W., Kim, S., Han, K., Ahn, S. S., Moon, J. H., Kim, E. H., Kim, J., Kang, S., Kim, S. H., Lee, S., et al. (2023) · European Radiology · doi:10.1007/s00330-023-10125-0 · Cited by 21 · see citing works
the POLA network, Appay, R., Tabouret, É., Touat, M., Carpentier, C., Colin, C., Ducray, F., Idbaïh, A., Mokhtari, K., Uro‐Coste, E., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0594-1 · Cited by 17 · see citing works
Self-citationBrat, D. J., Aldape, K., French, P. J., Louis, D. N., Nasrallah, M. P., Reifenberger, G., Reuß, D., Touat, M., van den Bent, M. J., Wesseling, P., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag108 · Cited by 17 · see citing works
Self-citationPreclinical Models of Low-Grade Gliomas
Dasgupta, P., Balasubramaniyan, V., de Groot, J. F., & Majd, N. (2023) · Cancers · doi:10.3390/cancers15030596 · Cited by 14 · see citing works
Update on treatment strategies for anaplastic glioma: a review of literature
Simonetti, G., Gaviani, P., Innocenti, A., Botturi, A., Lamperti, E., & Silvani, A. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1829-y · Cited by 14 · see citing works
Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma
Tabouret, É., Denicolaï, E., Delfino, C., Graillon, T., Boucard, C., Nanni, I., Padovani, L., Figarella-Branger, D. F., & Chinot, O. L. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2251-5 · Cited by 13 · see citing works
Self-citationFigarella-Branger, D. F., Mokhtari, K., Colin, C., Uro‐Coste, E., Jouvet, A., Dehais, C., Carpentier, C., Villa, C., Maurage, C., Eimer, S., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12227 · Cited by 12 · see citing works
Self-citationFigarella-Branger, D. F., Colin, C., Mokhtari, K., Uro‐Coste, E., Idbaïh, A., Appay, R., Tabouret, É., Touat, M., Seyve, A., Carpentier, C., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae221 · Cited by 12 · see citing works
Self-citationBillard, P., Guerriau, C., Carpentier, C., Juillard, F., Grandin, N., Lomonte, P., Kantapareddy, P., Dufay, N., Barritault, M., Rimokh, R., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.004 · Cited by 11 · see citing works
Self-citationRosenberg, S., Ducray, F., Alentorn, A., Dehais, C., Elarouci, N., Kamoun, A., Marie, Y., Tanguy, M., de Reyniès, A., Mokhtari, K., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0495 · Cited by 11 · see citing works
Self-citationMichaud, K., de Tayrac, M., D’Astous, M., Duval, C., Paquet, C., Samassékou, O., Gould, P. V., & Saïkali, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168728 · Cited by 10 · see citing works
Chanez, B., Appay, R., Guillé, A., Lagarde, A., Colin, C., Adélaı̈de, J., Denicolaï, E., Jiguet‐Jiglaire, C., Bequet, C., Graillon, T., et al. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120207 · Cited by 10 · see citing works
Self-citationPrognostic and predictive biomarkers in central nervous system tumours: the molecular state of play
Satgunaseelan, L., Sy, J. S., Shivalingam, B., Sim, H., Alexander, K. L., & Buckland, M. E. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.003 · Cited by 10 · see citing works
Michaud, K., de Tayrac, M., D’Astous, M., Paquet, C., Gould, P. V., & Saïkali, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193213 · Cited by 8 · see citing works
Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study
Garnier, L., Vidal, C., Chinot, O. L., Moyal, E. C., Djelad, A., Bronnimann, C., Bekaert, L., Taillandier, L., Frenel, J., Langlois, O., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac023 · Cited by 7 · see citing works
Self-citationMontégut, C., Guillamo, J., Ducray, F., Dehais, C., Moyal, E. C., Desenclos, C., Petit, A., Seizeur, R., Bekaert, L., Gaultier, C., et al. (2022) · Cancers · doi:10.3390/cancers14225509 · Cited by 7 · see citing works
Self-citationCell-Population Dynamics in Diffuse Gliomas during Gliomagenesis and Its Impact on Patient Survival
Nikitin, P. V., Musina, G. R., Игоревич, П. С., Kuzin, A. A., Popov, I. A., Belyaev, A. Y., Kobyakov, G. L., Usachev, D. Y., Nikolaev, V. N., & Mikhailov, V. P. (2022) · Cancers · doi:10.3390/cancers15010145 · Cited by 7 · see citing works
Le diagnostic histo-moléculaire des tumeurs gliales et glioneuronales
Métais, A., & Rousseau, A. (2021) · Annales de Pathologie · doi:10.1016/j.annpat.2020.12.008 · Cited by 7 · see citing works
Valvi, S., Fouladi, M., Fisher, M. J., & Gottardo, N. G. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1662414 · Cited by 10 · see citing works
Jin, L., Sun, T., Liu, X., Cao, Z., Liu, Y., Chen, H., Ma, Y., Zhang, J., Liu, Y., Liu, Y., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108041 · Cited by 6 · see citing works
A viral attack on brain tumors: the potential of oncolytic virus therapy
Mokhtarpour, K., Akbarzadehmoallemkolaei, M., & Rezaei, N. (2024) · Journal of NeuroVirology · doi:10.1007/s13365-024-01209-8 · Cited by 4 · see citing works
Gilhodes, J., Meola, A., Cabarrou, B., Peyraga, G., Dehais, C., Figarella-Branger, D. F., Ducray, F., Maurage, C., Loussouarn, D., Uro‐Coste, E., et al. (2023) · Cancers · doi:10.3390/cancers15123067 · Cited by 4 · see citing works
Self-citationMatek, D., Pevec, D., Boban-Blagaic, A., & Sikiric, P. (2025) · Biomedicines · doi:10.3390/biomedicines13010201 · Cited by 3 · see citing works
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas
Hoogstrate, Y., Ghisai, S. A., van Hijfte, L., Head, R., de Heer, I. J., Padovan, M., de Wit, M., Vallentgoed, W., Dipasquale, A., Wijnenga, M. M. J., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102682 · Cited by 2 · see citing works
An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative
Haddad, P., Shahzadi, S., Samiei, F., Kharazi, H. H., Tabatabaeefar, M., Rakhsha, A., Faranoush, M., Torabi-Nami, M., Dadras, A., & Nafarieh, L. (2015) · Europe PMC (PubMed Central) · doi:10.13140/rg.2.1.2111.6961 · Cited by 2 · see citing works
Updates Treatment of Low-Grade Glioma
Hervey‐Jumper, S. L., & Berger, M. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-54879-7_22 · Cited by 2 · see citing works
Sathornsumetee, S., Cheunsuchon, P., & Sangruchi, T. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.02.069 · Cited by 2 · see citing works
Hervey‐Jumper, S. L., van den Bent, M. J., Mehta, M. P., & Berger, M. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-04152-6_9 · Cited by 2 · see citing works
Le réseau POLA : un projet national pour les tumeurs oligodendrogliales de haut grade
Delattre, J., Dehais, C., Ducray, F., & Figarella-Branger, D. F. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.10.010 · Cited by 2 · see citing works
Self-citationFast-growing oligodendrogliomas are aggressive tumors—the real life biomarker?
Geurts, M., & van den Bent, M. J. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa097 · Cited by 2 · see citing works
Bertucci, A., Dufour, O., Appay, R., Harlay, V., Ducray, F., Bronnimann, C., Djelad, A., Moyal, E. C., Campone, M., Langlois, O., et al. (2025) · Cancer · doi:10.1002/cncr.35814 · Cited by 1 · see citing works
Self-citationChromosomal defects track tumor subpopulations and change in progression in oligodendroglioma
Nauen, D. W., Guajardo, A., Haley, L. M., Powell, K., Burger, P. C., & Gocke, C. D. (2015) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/1/1/015001 · Cited by 1 · see citing works
Chamberlain, M. C. (2015) · CNS Oncology · doi:10.2217/cns.14.52
Prisciandaro, J. I., Zoberi, J. E., Cohen, G. N., Kim, Y., Johnson, P. B., Paulson, E. S., Song, W. Y., Hwang, K., Erickson, B. E., Beriwal, S., et al. (2022) · Medical Physics · doi:10.1002/mp.15991
Ortiz, L. D., Pareja, D. A. G., Sánchez, R. G. P., Yepes, C. J., & Flórez, P. M. A. (2023) · Medicina UPB · doi:10.18566/medupb.v42n1.a11
Witten, A. J., Dougherty, C., & Hao, C. (2024) · Neuropathology · doi:10.1111/neup.12996
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
Wick, W., & Reifenberger, G. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780198869702.003.0005
Michaud, K., Gould, P. V., D’Astous, M., Paquet, C., & Saïkali, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0322809
Choi, S. H., Lee, N., Choi, K., Han, K., Shin, N.-Y., Ahn, S. S., Yoon, H. I., Chang, J. H., Kim, S. H., Lee, S., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11768-x
Salgado, M. Á. V., Sepulveda, J. M., Earl, J., Flores, J. N. G., Ruano, Y., Pian, H. G., Cantero, D., Segura‐Collar, B., Gargini, R., & Hernández‐Laín, A. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf380
- Authors
- Figarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Forest, F., Maurage, C.-A., Vignaud, J.-M., Polivka, M., Lechapt-Zalcman, E., Eimer, S., Viennet, G., Quintin-Roue, I., Aubriot-Lorton, M.-H., Diebold, M.-D., Loussouarn, D., Lacroix, C., Rigau, V., Laquerriere, A., Vandenbos, F., Michalak, S., Sevestre, H., Peoch, M., Labrousse, F., Christov, C., Kemeny, J.-L., Chenard, M.-P., Chiforeanu, D., Ducray, F., Idbaih, A., Desenclos, C., Menei, P., Al Nader, E., Godard, J., Servagi-Vernat, S., Carpentier, A., Loiseau, H., Dam-Hieu, P., Guillamo, J. S., Emery, E., Verelle, P., Durando, X., Faillot, T., Le Guerinel, C., Ghiringhelli, F., Parker, F., Adam, C., Dubois, F., Ramirez, C., Gueye, E. M., Honnorat, J., Chinot, O., Bauchet, L., Beauchesne, P., Campone, M., Frenel, J. S., Fontaine, D., Campello, C., Roger, P., Heitzmann, A., Fesneau, M., Delattre, J. Y., Elouadhani-Hamdi, S., Ricard, D., Colin, P., Vauleon, E., Langlois, O., Fotso, M. J. M., Andraud, M., Mouton, S., Noel, G., Desse, N., Soulard, R., Cohen-Moyal, E., Lubrano, V., Dhermain, F., & the POLA Network
- Affiliations
- Inserm (FR)
- Centre de Recherche en Neurosciences de Lyon (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Aix-Marseille Université (FR)
- ORCID
- Figarella-Branger, D.
- Mokhtari, K.
- Dehais, C.
- Colin, C.
- Forest, F.
- Maurage, C.-A.
- Loussouarn, D.
- Rigau, V.
- Labrousse, F.
- Christov, C.
- Chenard, M.-P.
- Ducray, F.
- Servagi-Vernat, S.
- Carpentier, A.
- Loiseau, H.
- Durando, X.
- Ghiringhelli, F.
- Adam, C.
- Honnorat, J.
- Chinot, O.
- Bauchet, L.
- Beauchesne, P.
- Campone, M.
- Frenel, J. S.
- Fontaine, D.
- Roger, P.
- Colin, P.
- Langlois, O.
- Desse, N.
- Lubrano, V.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-09
- Volume
- 16
- Issue
- 9
- Pages
- 1244-1254
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC4136899
- OpenAlex
- W2161476194
- Cited by
- 63
- References
- 27
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 8 · 2015: 7 · 2014: 3
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale (INCa-DGOS-Inserm 6038)
- Centre Hospitalier Régional Universitaire de Montpellier
- Institut National Du Cancer (INCa-DGOS-INSERM-6038)
- Direction Générale de l’offre de Soins
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- anaplastic oligodendroglioma, 1p/19q codeletion, mitotic index, microvascular proliferation, necrosis, histological heterogeneity, IDH mutation, alpha-internexin, chromosomal instability, Ki-67 proliferation index, prognostic stratification, overall survival, progression-free survival
- MeSH terms
- Brain, Brain Neoplasms, Chromosome Deletion, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, Humans, Isocitrate Dehydrogenase, Mitotic Index, Necrosis, Neovascularization, Pathologic, Oligodendroglioma, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
